Lotus Pharmaceutical Co (美時製藥) yesterday said it has signed an exclusive marketing agreement with Finland-based Orion Oyj for the distribution of its drugs to treat Parkinson’s disease in select Asian markets.
Lotus is to help Orion sell and distribute its branded drug Stalevo in Taiwan, Bangladesh, Hong Kong, Indonesia, the Philippines, South Korea and Vietnam, it said in a statement.
The company is also to sell Orion’s Comtan, another drug used to treat Parkinson’s disease, in Taiwan, Hong Kong, the Philippines and South Korea, it added.
Novartis Pharma AG currently holds the rights to sell and distribute the two proprietary drugs in those markets.
Those rights are to be transferred to Lotus in the third quarter of next year, the firm said.
“Novartis marketed Stalevo as a second-line treatment for Parkinson’s disease in those countries, which are recommended by doctors when the first-line therapy does not work,” Lotus acting spokeswoman Nadiya Chen (陳荻雅) told the Taipei Times by telephone.
“However, Orion expects the drug to be used as a first-line treatment. That was the main reason why the Finnish company looked to change its marketing partner and sought our help,” Chen said.
Stalevo, which contains active pharmaceutical ingredients including levodopa, carbidopa and entacapone, has been used as a first-line drug in several overseas markets after Orion marketed the drug itself following its acquisition of the sales rights from Novartis last year, she added.
According to the agreement signed by Orion and Lotus, Orion would be responsible for manufacturing the products and the agreement would be in effect for five years following the first commercial sales.
Lotus expects sales of Stalevo to boost its revenue in the next few years, given the huge market for Parkinson’s treatment, Chen said.
The market was approximately US$1.04 billion across Asia last year and is estimated to increase at a compound annual growth rate of 6.8 percent, reaching US$1.44 billion by 2023, according to research firm Market Data Forecast, she said.
“Despite the heavy competition in Parkinson’s disease treatment, with many generic drugs in the market, we are confident about Stalevo and Comtan, as they are among the most frequently prescribed drugs,” Chen said.
Lotus sees Roche’s Madopar as Stalevo’s biggest rival in those Asian markets, but is not concerned about competition from generic drugs as many doctors and patients prefer branded drugs, she said.
While this is the first cooperation agreement between Lotus and Orion, the Taiwanese firm has partnerships with other companies to market their branded drugs, including Aclasta and Evista, which are used to treat osteoporosis, and Mercilon, a combined contraceptive pill.
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Intel Corp has named Tasha Chuang (莊蓓瑜) to lead Intel Taiwan in a bid to reinforce relations between the company and its Taiwanese partners. The appointment of Chuang as general manager for Intel Taiwan takes effect on Thursday, the firm said in a statement yesterday. Chuang is to lead her team in Taiwan to pursue product development and sales growth in an effort to reinforce the company’s ties with its partners and clients, Intel said. Chuang was previously in charge of managing Intel’s ties with leading Taiwanese PC brand Asustek Computer Inc (華碩), which included helping Asustek strengthen its global businesses, the company
Taiwanese suppliers to Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) are expected to follow the contract chipmaker’s step to invest in the US, but their relocation may be seven to eight years away, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. When asked by opposition Chinese Nationalist Party (KMT) Legislator Niu Hsu-ting (牛煦庭) in the legislature about growing concerns that TSMC’s huge investments in the US will prompt its suppliers to follow suit, Kuo said based on the chipmaker’s current limited production volume, it is unlikely to lead its supply chain to go there for now. “Unless TSMC completes its planned six
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new
RSS